1. Home
  2. DVAX vs RVLV Comparison

DVAX vs RVLV Comparison

Compare DVAX & RVLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DVAX
  • RVLV
  • Stock Information
  • Founded
  • DVAX 1996
  • RVLV 2003
  • Country
  • DVAX United States
  • RVLV United States
  • Employees
  • DVAX N/A
  • RVLV N/A
  • Industry
  • DVAX Biotechnology: Pharmaceutical Preparations
  • RVLV Catalog/Specialty Distribution
  • Sector
  • DVAX Health Care
  • RVLV Consumer Discretionary
  • Exchange
  • DVAX Nasdaq
  • RVLV Nasdaq
  • Market Cap
  • DVAX 1.3B
  • RVLV 1.4B
  • IPO Year
  • DVAX 2004
  • RVLV 2019
  • Fundamental
  • Price
  • DVAX $9.70
  • RVLV $23.81
  • Analyst Decision
  • DVAX Buy
  • RVLV Buy
  • Analyst Count
  • DVAX 4
  • RVLV 14
  • Target Price
  • DVAX $26.50
  • RVLV $26.79
  • AVG Volume (30 Days)
  • DVAX 1.9M
  • RVLV 1.0M
  • Earning Date
  • DVAX 11-06-2025
  • RVLV 11-04-2025
  • Dividend Yield
  • DVAX N/A
  • RVLV N/A
  • EPS Growth
  • DVAX N/A
  • RVLV 38.54
  • EPS
  • DVAX N/A
  • RVLV 0.63
  • Revenue
  • DVAX $316,268,000.00
  • RVLV $1,182,554,000.00
  • Revenue This Year
  • DVAX $23.23
  • RVLV $9.12
  • Revenue Next Year
  • DVAX $16.57
  • RVLV $6.65
  • P/E Ratio
  • DVAX N/A
  • RVLV $37.58
  • Revenue Growth
  • DVAX 26.66
  • RVLV 10.68
  • 52 Week Low
  • DVAX $9.20
  • RVLV $16.80
  • 52 Week High
  • DVAX $14.63
  • RVLV $39.58
  • Technical
  • Relative Strength Index (RSI)
  • DVAX 41.54
  • RVLV 58.91
  • Support Level
  • DVAX $9.20
  • RVLV $22.31
  • Resistance Level
  • DVAX $9.94
  • RVLV $24.01
  • Average True Range (ATR)
  • DVAX 0.30
  • RVLV 0.93
  • MACD
  • DVAX -0.05
  • RVLV 0.06
  • Stochastic Oscillator
  • DVAX 40.65
  • RVLV 84.42

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

About RVLV Revolve Group Inc.

Revolve Group Inc is an emerging e-commerce retailer, selling women's dresses, handbags, shoes, beauty products, and incidentals across its marketplace properties, Revolve and FWRD. The platform is built to suit the "next-generation customer," emphasizing mobile commerce, influencer marketing, and occupying an aspirational but attainable luxury niche. With $1.1 billion in 2024 net sales, the firm sits just outside the top 30 apparel retailers (by sales) in the U.S, but has consistently generated robust top-line growth as the industry continues to favor digital channels. Revolve generates approximately 18% of sales from private-label offerings, while focusing on building an inventory of distinctive products from emerging fashion brands with less than $10 million in annual sales.

Share on Social Networks: